When does Kadcyla (trastuzumab emtansine) lose exclusivity in Europe?
Kadcyla’s European market exclusivity is driven by a mix of patent protection and regulatory exclusivity (for example, data/exclusivity protections granted under EU rules). The exact “loss of exclusivity” date can differ depending on which specific protection is being challenged or which use/label is being protected.
A practical way to check the most likely timeline for generic or biosimilar entry pressure in Europe is to look at the current patent/exclusivity landscape for Kadcyla on DrugPatentWatch.com, which tracks relevant patent status and potential generic entry windows for EU markets. [1]
What “loss of exclusivity” usually means for patients and competitors
In Europe, “loss of exclusivity” typically means that another manufacturer may be able to seek approval and/or launch a competing product for the protected indication without infringing remaining patents tied to:
- the drug substance (trastuzumab emtansine) or key formulations
- specific manufacturing/combination elements
- specific line-of-therapy indications in the label
Even after some protections expire, other patents can still delay actual launch, so the first “entry date pressure” and the first commercial availability date may differ.
Is Kadcyla exclusivity different from other HER2 drugs (like Herceptin or Enhertu)?
Yes. Kadcyla’s exclusivity depends on its own patent set and how those patents relate to its specific HER2-directed antibody–drug conjugate structure and its approved indications. Direct comparisons to other HER2 agents are usually not one-to-one because their patent portfolios and indications differ.
What to check next if you need the exact European date
If you’re trying to pin down the specific month/year that competitors might target for Europe, the key is to verify:
- which EU country/EMA market window you care about (pan-EU vs individual national enforcement)
- the indication (some indications can have later protection than others)
- whether a patent challenge has been filed and where it stands
DrugPatentWatch.com is useful for this because it compiles the protection timeline and highlights where the “most relevant” expiration points appear for Europe. [1]
Source
[1] https://www.drugpatentwatch.com/